Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Grieskirchen – page 33

452 clinical trials in Grieskirchen, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Grieskirchen at a glance
452
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

452 trials in Grieskirchen

Open in trial search

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Astrazeneca AB

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AC102
  • Sponsor:AudioCure Pharma GmbH

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Study on the Long-Term Safety of Seladelpar for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Grieskirchen

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on Chronic Obstructive Pulmonary Disease (COPD) management and treatment optimization. Clinical trials are evaluating new therapeutic approaches for patients with moderate to severe conditions.

  • COPD Exacerbation Management
  • Triple Therapy Enhancement
  • Advanced Treatment Options

Studies aim to improve quality of life for patients with chronic respiratory conditions through targeted interventions.

02 Pulmonary Therapeutics

Research investigating novel treatments for chronic bronchitis and associated respiratory conditions. Trials focus on evaluating the effectiveness of maintenance therapies and new drug combinations.

  • Treatment Efficacy Assessment
  • Long-term Safety Studies
  • Therapeutic Combinations

Current studies examine both established and innovative approaches to respiratory disease management.

03 Advanced COPD Research

Specialized trials examining severe COPD with frequent exacerbations. Research focuses on patients with elevated peripheral blood eosinophils and explores targeted biological treatments.

  • Biological Therapy Evaluation
  • Exacerbation Prevention
  • Biomarker Studies

These studies aim to develop more effective treatments for severe cases of respiratory disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.